SGI and its business units have developed key partnerships and agreements with multiple industry leaders. For more information about our business and how to partner with us, please contact our Corporate Development team at firstname.lastname@example.org.
Creating novel solutions and transforming existing products
Flu Vaccines, Gene/Cell Therapy, Biologics, Organ Transplants, Antimicrobials
Dietary Supplements, Food Ingredients, Omega 3 Oils, Algal Protein
Renewable Chemicals, Bio-based Intermediates, Plant Enhancement and Protection, Algal Biofuel
Developing products containing Omega-3 Docosahexaenoic Acid (DHA) from a non-genetically modified algae strain.
SGI and ExxonMobil are focused on researching and developing naturally occurring and conventionally modified algae strains for use in developing algae-based biofuels.
SGI, JCVI and GSK are collaborating to develop and evaluate multivalent RNA-based vaccines for protection against a highly diverse infectious disease pathogen.
SGI employed synthetic genomics tools and technologies developed by our team to accelerate the production of the influenza vaccine seeds required for vaccine manufacturing.
SGI and United Therapeutics have joined together to address the critical unmet organ need through xenotransplantation, the use of pigs as an essentially unlimited source of donor organs.